Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

106 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Fifth Ovarian Cancer Consensus Conference: individualized therapy and patient factors.
McGee J, Bookman M, Harter P, Marth C, McNeish I, Moore KN, Poveda A, Hilpert F, Hasegawa K, Bacon M, Gatsonis C, Brand A, Kridelka F, Berek J, Ottevanger N, Levy T, Silverberg S, Kim BG, Hirte H, Okamoto A, Stuart G, Ochiai K; participants of the 5th Ovarian Cancer Consensus Conference. McGee J, et al. Among authors: kridelka f. Ann Oncol. 2017 Apr 1;28(4):702-710. doi: 10.1093/annonc/mdx010. Ann Oncol. 2017. PMID: 28119296 Free article.
Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup.
Vergote I, Gonzalez-Martin A, Lorusso D, Gourley C, Mirza MR, Kurtz JE, Okamoto A, Moore K, Kridelka F, McNeish I, Reuss A, Votan B, du Bois A, Mahner S, Ray-Coquard I, Kohn EC, Berek JS, Tan DSP, Colombo N, Zang R, Concin N, O'Donnell D, Rauh-Hain A, Herrington CS, Marth C, Poveda A, Fujiwara K, Stuart GCE, Oza AM, Bookman MA; participants of the 6th Gynecologic Cancer InterGroup (GCIG) Ovarian Cancer Consensus Conference on Clinical Research. Vergote I, et al. Among authors: kridelka f. Lancet Oncol. 2022 Aug;23(8):e374-e384. doi: 10.1016/S1470-2045(22)00139-5. Lancet Oncol. 2022. PMID: 35901833 Free PMC article. Review.
Survival with Cemiplimab in Recurrent Cervical Cancer.
Tewari KS, Monk BJ, Vergote I, Miller A, de Melo AC, Kim HS, Kim YM, Lisyanskaya A, Samouëlian V, Lorusso D, Damian F, Chang CL, Gotovkin EA, Takahashi S, Ramone D, Pikiel J, Maćkowiak-Matejczyk B, Guerra Alía EM, Colombo N, Makarova Y, Rischin D, Lheureux S, Hasegawa K, Fujiwara K, Li J, Jamil S, Jankovic V, Chen CI, Seebach F, Weinreich DM, Yancopoulos GD, Lowy I, Mathias M, Fury MG, Oaknin A; Investigators for GOG Protocol 3016 and ENGOT Protocol En-Cx9. Tewari KS, et al. N Engl J Med. 2022 Feb 10;386(6):544-555. doi: 10.1056/NEJMoa2112187. N Engl J Med. 2022. PMID: 35139273 Clinical Trial.
A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancer.
Vergote I, Schilder RJ, Pippitt CH Jr, Wong S, Gordon AN, Scudder S, Kridelka F, Dirix L, Leach JW, Ananda S, Nanayakkara N, Melara R, Bass MB, Litten J, Adewoye H, Wenham RM. Vergote I, et al. Among authors: kridelka f. Gynecol Oncol. 2014 Oct;135(1):25-33. doi: 10.1016/j.ygyno.2014.07.003. Epub 2014 Jul 11. Gynecol Oncol. 2014. PMID: 25019569 Free article. Clinical Trial.
Added value of para-aortic surgical staging compared to 18F-FDG PET/CT on the external beam radiation field for patients with locally advanced cervical cancer: An ONCO-GF study.
De Cuypere M, Lovinfosse P, Goffin F, Gennigens C, Rovira R, Duch J, Fastrez M, Gebhart G, Squifflet JL, Luyckx M, Charaf G, Crener K, Buxant F, Bucella D, Jouret M, Hustinx R, Kridelka F. De Cuypere M, et al. Among authors: kridelka f. Eur J Surg Oncol. 2020 May;46(5):883-887. doi: 10.1016/j.ejso.2019.11.496. Epub 2019 Nov 11. Eur J Surg Oncol. 2020. PMID: 31784203
Phase II study of weekly paclitaxel/carboplatin in combination with prophylactic G-CSF in the treatment of gynecologic cancers: A study in 108 patients by the Belgian Gynaecological Oncology Group.
Vergote I, Debruyne P, Kridelka F, Berteloot P, Amant F, Honhon B, Lybaert W, Leunen K, Geldhof K, Verhoeven D, Forget F, Vuylsteke P, D'Hondt L, Huizing M, Van den Bulck H, Laenen A. Vergote I, et al. Among authors: kridelka f. Gynecol Oncol. 2015 Aug;138(2):278-84. doi: 10.1016/j.ygyno.2015.05.042. Epub 2015 Jun 4. Gynecol Oncol. 2015. PMID: 26049123 Clinical Trial.
Importance of pathological review of gestational trophoblastic diseases: results of the Belgian Gestational Trophoblastic Diseases Registry.
Schoenen S, Delbecque K, Van Rompuy AS, Marbaix E, Noel JC, Delvenne P, Moerman P, Vergote I, Kridelka F, Vandewal A, Han S, Goffin F. Schoenen S, et al. Among authors: kridelka f. Int J Gynecol Cancer. 2022 Apr 29:ijgc-2021-003312. doi: 10.1136/ijgc-2021-003312. Online ahead of print. Int J Gynecol Cancer. 2022. PMID: 35487585
Curative effect of second curettage for treatment of gestational trophoblastic disease - Results of the Belgian registry for gestational trophoblastic disease.
Vandewal A, Delbecque K, Van Rompuy AS, Noel JC, Marbaix E, Delvenne P, Nisolle M, Van Nieuwenhuysen E, Kridelka F, Vergote I, Goffin F, Han SN. Vandewal A, et al. Among authors: kridelka f. Eur J Obstet Gynecol Reprod Biol. 2021 Feb;257:95-99. doi: 10.1016/j.ejogrb.2020.12.001. Epub 2020 Dec 8. Eur J Obstet Gynecol Reprod Biol. 2021. PMID: 33383413 Free article.
Clinical efficacy and toxicity of radio-chemotherapy and magnetic resonance imaging-guided brachytherapy for locally advanced cervical cancer patients: A mono-institutional experience.
Lakosi F, de Cuypere M, Viet Nguyen P, Jansen N, Warlimont B, Gulyban A, Gennigens C, Seidel L, Delbecque K, Coucke P, Hermesse J, Kridelka F. Lakosi F, et al. Among authors: kridelka f. Acta Oncol. 2015;54(9):1558-66. doi: 10.3109/0284186X.2015.1062542. Epub 2015 Sep 25. Acta Oncol. 2015. PMID: 26406152
106 results